GLP-1 receptor agonist 1
Code | Size | Price |
---|
TAR-T11408-1mg | 1mg | £856.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T11408-5mg | 5mg | £2,601.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T11408-10mg | 10mg | £3,934.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T11408-25mg | 25mg | £5,797.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T11408-50mg | 50mg | £7,805.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T11408-100mg | 100mg | £10,352.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
GLP-1 receptor agonist 1 is a GLP-1 receptor agonist .
CAS:
2212020-52-3
Formula:
C48H48F2N10O5
Long Description:
GLP-1RA and SGLT-2i are new diabetes medications that have gained widespread attention due to their cardiovascular and renal benefits brought to patients with type 2 diabetes (T2D). Orforglipron, also known as LY3502970, is a GLP-1 receptor agonist. It is used in research related to obesity and T2D.
Molecular Weight:
882.974
Pathway:
GPCR/G Protein
Purity:
0.98
Research Area:
Obesity , T2D
SMILES:
C[C@H]1C[C@]1(c1noc(=O)[nH]1)n1c(cc2cc(ccc12)[C@H]1CCOC(C)(C)C1)C(=O)N1CCc2nn(c(c2[C@@H]1C)-n1ccn(-c2ccc3n(C)ncc3c2F)c1=O)-c1cc(C)c(F)c(C)c1
Target:
Glucagon Receptor
References
1. Pyrazolopyridine derivative having glp-1 receptor agonist effect. WO2013046136A1.